| Israel | Turki | Austria | |
| Imunoterapi | dari $2,400 | dari $2,200 | dari $30,000 |
| Imunoterapi untuk kanker prostat | dari $2,250 | dari $12,000 | dari $30,000 |
| Imunoterapi dengan Keytruda (Pembrolizumab) | dari $9,800 | dari $3,300 | dari $15,000 |
| Terapi biologis | - | dari $5,500 | dari $20,000 |
| Terapi Bacillus Calmette-Guérin (BCG) | - | dari $1,200 | dari $2,400 |
Bookimed tidak menambah biaya tambahan dalam harga Imunoterapi. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik untuk Imunoterapi Anda saat tiba.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam Imunoterapi dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan Imunoterapi Anda.
Bookimed, sebuah platform pariwisata medis global terkemuka, berkomitmen untuk membantu klien yang mencari Imunoterapi di Israel dengan menawarkan bantuan ahli dan solusi medis yang dapat dipercaya untuk setiap situasi. Sistem peringkat otomatis cerdas digunakan untuk menyusun daftar klinik yang transparan, dengan cermat dipelihara oleh ilmuwan data menggunakan AI untuk keakuratan. Platform ini menjamin keaslian dengan menerbitkan ulasan dari pasien yang sebenarnya setelah perawatan mereka. Bookimed menawarkan solusi medis yang komprehensif, dengan pembaruan dari klinik untuk memastikan keandalan. Konten tentang Imunoterapi di Israel, yang dibuat oleh penulis medis berpengalaman dan ditinjau oleh spesialis, sesuai dengan Pedoman Editorial Bookimed, mencerminkan komitmen platform untuk menyajikan informasi kesehatan yang berkualitas tinggi dan jelas. Untuk informasi lebih lanjut atau pertanyaan, jangan ragu untuk menghubungi kami di marketing@bookimed.com atau pelajari lebih lanjut tentang kami dan misi kami di sini.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).
His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.
He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.
He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.
Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.
He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.
He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.